Veracyte, Inc. (FRA:12V)

Veracyte Statistics

Total Valuation

Veracyte has a market cap or net worth of EUR 3.15 billion. The enterprise value is 2.87 billion.

Market Cap	3.15B
Enterprise Value	2.87B

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	79.05M
Shares Outstanding	n/a
Shares Change (YoY)	+6.32%
Shares Change (QoQ)	+1.66%
Owned by Insiders (%)	0.47%
Owned by Institutions (%)	114.57%
Float	78.64M

Valuation Ratios

The trailing PE ratio is 122.08 and the forward PE ratio is 27.95.

PE Ratio	122.08
Forward PE	27.95
PS Ratio	7.47
PB Ratio	2.94
P/TBV Ratio	9.30
P/FCF Ratio	37.69
P/OCF Ratio	34.19
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.08, with an EV/FCF ratio of 34.34.

EV / Earnings	111.23
EV / Sales	6.75
EV / EBITDA	39.08
EV / EBIT	64.22
EV / FCF	34.34

Financial Position

The company has a current ratio of 6.23, with a Debt / Equity ratio of 0.03.

Current Ratio	6.23
Quick Ratio	5.74
Debt / Equity	0.03
Debt / EBITDA	0.47
Debt / FCF	0.41
Interest Coverage	52,046.32

Financial Efficiency

Return on equity (ROE) is 2.49% and return on invested capital (ROIC) is 2.61%.

Return on Equity (ROE)	2.49%
Return on Assets (ROA)	2.46%
Return on Invested Capital (ROIC)	2.61%
Return on Capital Employed (ROCE)	4.02%
Revenue Per Employee	512,146
Profits Per Employee	31,358
Employee Count	824
Asset Turnover	0.37
Inventory Turnover	7.13

Taxes

In the past 12 months, Veracyte has paid 590,644 in taxes.

Income Tax	590,644
Effective Tax Rate	2.23%

Stock Price Statistics

The stock price has increased by +0.49% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+0.49%
50-Day Moving Average	32.34
200-Day Moving Average	27.45
Relative Strength Index (RSI)	67.69
Average Volume (20 Days)	22

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.58

Income Statement

In the last 12 months, Veracyte had revenue of EUR 422.01 million and earned 25.84 million in profits. Earnings per share was 0.32.

Revenue	422.01M
Gross Profit	298.38M
Operating Income	44.34M
Pretax Income	26.43M
Net Income	25.84M
EBITDA	63.41M
EBIT	44.34M
Earnings Per Share (EPS)	0.32

Balance Sheet

The company has 312.31 million in cash and 34.48 million in debt, giving a net cash position of 277.83 million.

Cash & Cash Equivalents	312.31M
Total Debt	34.48M
Net Cash	277.83M
Net Cash Per Share	n/a
Equity (Book Value)	1.07B
Book Value Per Share	13.56
Working Capital	321.38M

Cash Flow

In the last 12 months, operating cash flow was 92.26 million and capital expenditures -8.56 million, giving a free cash flow of 83.70 million.

Operating Cash Flow	92.26M
Capital Expenditures	-8.56M
Free Cash Flow	83.70M
FCF Per Share	n/a

Margins

Gross margin is 70.70%, with operating and profit margins of 10.51% and 6.12%.

Gross Margin	70.70%
Operating Margin	10.51%
Pretax Margin	6.26%
Profit Margin	6.12%
EBITDA Margin	15.03%
EBIT Margin	10.51%
FCF Margin	19.83%

Dividends & Yields

Veracyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.32%
Shareholder Yield	-6.32%
Earnings Yield	0.82%
FCF Yield	2.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Veracyte has an Altman Z-Score of 14.54 and a Piotroski F-Score of 7.

Altman Z-Score	14.54
Piotroski F-Score	7